The study will examine the vaccine’s safety and ability to generate an immune response.
The Coalition for Epidemic Preparedness Innovations intends to develop and stockpile vaccines against three known viral threats, and support the development of technology to manufacture large amounts of vaccine quickly when needed.
Researchers are using low-energy-electrons to irradiate pathogens which produces no toxic waste and provides a faster way of rendering pathogens inactive.
Much about the behavior of the Zika virus is unknown because it is unknown how much circulation of Zika there has been in the past in areas of the world outside the Americas.
Researchers are scrambling to develop a Zika vaccine.
The race to develop a vaccine against the Zika virus is fueled by the potential profit.
Epidemiology and Burden of Disease
New and Emerging Vaccines
Preclinical and Clinical Trials
Delivery Vaccine Safety
Vaccine efficacy may be improved by exploiting cross-reactive antibodies.
Researchers have discovered an immune antibody that can evolve to neutralize a wide array of influenza virus strains.
Researchers tested vaccines against Ebola and H1N1 flu that were effective in lab mice, and have also tested a RNA vaccine for Zika that had successful results.